[1]
|
Kerr, T.A. and Davidson, N.O. (2012) Cholesterol and Nonalcoholic Fatty Liver Disease: Renewed Focus on an Old Villain. Hepatology, 56, 1995-1998. https://doi.org/10.1002/hep.26088
|
[2]
|
Eguchi, Y., Hyogo, H., Ono, M., et al. (2012) Prevalence and Associated Metabolic Factors of Nonalcoholic Fatty Liver Disease in the General Population from 2009 to 2010 in Japan: A Multicenter Large Retrospective Study. Journal of Gastroenterology, 47, 586-595. https://doi.org/10.1007/s00535-012-0533-z
|
[3]
|
Estes, C., Anstee, Q.M., Arias-Loste, M.T., et al. (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016-2030. Journal of Hepatology, 69, 896-904. https://doi.org/10.1016/j.jhep.2018.05.036
|
[4]
|
Qiu, Y., Sui, X., Zhan, Y., et al. (2017) Steroidogenic Acute Regulatory Protein (StAR) Overexpression Attenuates HFD-Induced Hepatic Steatosis and Insulin Resistance. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1863, 978-990. https://doi.org/10.1016/j.bbadis.2017.01.026
|
[5]
|
路晓荣, 李剑勇. 动物机体胆固醇代谢调控机制研究进展[J]. 动物医学进展, 2019, 40(7): 101-107.
|
[6]
|
Maxfield, F.R. and Tabas, I. (2005) Role of Cholesterol and Lipid Organization in Disease. Nature, 438, 612-621.
https://doi.org/10.1038/nature04399
|
[7]
|
Kapourchali, F.R., Surendiran, G., Goulet, A. and Moghadasian, M.H. (2016) The Role of Dietary Cholesterol in Lipoprotein Metabolism and Related Metabolic Abnormalities: A Mini-Review. Critical Reviews in Food Science and Nutrition, 56, 2408-2415. https://doi.org/10.1080/10408398.2013.842887
|
[8]
|
Trapani, L., Segatto, M. and Pallottini, V. (2012) Regulation and Deregulation of Cholesterol Homeostasis: The Liver as a Metabolic “Power Station”. World Journal of Hepatology, 4, 184-190. https://doi.org/10.4254/wjh.v4.i6.184
|
[9]
|
Zhou, F. and Sun, X. (2021) Cholesterol Metabolism: A Double-Edged Sword in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 9, Article ID: 762828. https://doi.org/10.3389/fcell.2021.762828
|
[10]
|
Malhotra, P., Gill, R.K., Saksena, S. and Alrefai, W.A. (2020) Disturbances in Cholesterol Homeostasis and Non-Alcoholic Fatty Liver Diseases. Frontiers in Medicine, 7, Article No. 467.
https://doi.org/10.3389/fmed.2020.00467
|
[11]
|
Alkhouri, N., Dixon, L.J. and Feldstein, A.E. (2009) Lipotoxicity in Nonalcoholic Fatty Liver Disease: Not All Lipids Are Created Equal. Expert Review of Gastroenterology & Hepatology, 3, 445-451. https://doi.org/10.1586/egh.09.32
|
[12]
|
Takakura, K., Oikawa, T., Nakano, M., et al. (2019) Recent Insights into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma. Frontiers in Oncology, 9, Article No. 762.
https://doi.org/10.3389/fonc.2019.00762
|
[13]
|
Min, H.K., Kapoor, A., Fuchs, M., et al. (2012) Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease. Cell Metabolism, 15, 665-674.
https://doi.org/10.1016/j.cmet.2012.04.004
|
[14]
|
Liu, M.X., Gao, M., Li, C.Z., et al. (2017) Dicer1/miR-29/HMGCR Axis Contributes to Hepatic Free Cholesterol Accumulation in Mouse Non-Alcoholic Steatohepatitis. Acta Pharmacologica Sinica, 38, 660-671.
https://doi.org/10.1038/aps.2016.158
|
[15]
|
Johnson, B.M. and DeBose-Boyd, R.A. (2018) Underlying Mechanisms for Sterol-Induced Ubiquitination and ER-Associated Degradation of HMG CoA Reductase. Seminars in Cell & Developmental Biology, 81, 121-128.
https://doi.org/10.1016/j.semcdb.2017.10.019
|
[16]
|
Sun, C., Huang, F., Liu, X., et al. (2015) MiR-21 Regulates Triglyceride and Cholesterol Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting HMGCR. International Journal of Molecular Medicine, 35, 847-853.
https://doi.org/10.3892/ijmm.2015.2076
|
[17]
|
Takei, A., Nagashima, S., Takei, S., et al. (2020) Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice. Diabetes, 69, 158-164.
https://doi.org/10.2337/db19-0076
|
[18]
|
Enjoji, M., Yasutake, K., Kohjima, M. and Nakamuta, M. (2012) Nutrition and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol. International Journal of Hepatology, 2012, Article ID: 925807.
https://doi.org/10.1155/2012/925807
|
[19]
|
Marí, M., Caballero, F., Colell, A., et al. (2006) Mitochondrial Free Cholesterol Loading Sensitizes to TNF- and Fas-Mediated Steatohepatitis. Cell Metabolism, 4, 185-198. https://doi.org/10.1016/j.cmet.2006.07.006
|
[20]
|
Brown, M.S., Radhakrishnan, A. and Goldstein, J.L. (2018) Retrospective on Cholesterol Homeostasis: The Central Role of Scap. Annual Review of Biochemistry, 87, 783-807. https://doi.org/10.1146/annurev-biochem-062917-011852
|
[21]
|
Van Rooyen, D.M. and Farrell, G.C. (2011) SREBP-2: A Link between Insulin Resistance, Hepatic Cholesterol, and Inflammation in NASH. Journal of Gastroenterology and Hepatology, 26, 789-792.
https://doi.org/10.1111/j.1440-1746.2011.06704.x
|
[22]
|
Nakamuta, M., Fujino, T., Yada, R., et al. (2009) Impact of Cholesterol Metabolism and the LXRalpha-SREBP-1c Pathway on Nonalcoholic Fatty Liver Disease. International Journal of Molecular Medicine, 23, 603-608.
https://doi.org/10.3892/ijmm_00000170
|
[23]
|
Zhao, L., Chen, Y., Tang, R., et al. (2011) Inflammatory Stress Exacerbates Hepatic Cholesterol Accumulation via Increasing Cholesterol Uptake and de Novo Synthesis. Journal of Gastroenterology and Hepatology, 26, 875-883.
https://doi.org/10.1111/j.1440-1746.2010.06560.x
|
[24]
|
Cheung, O., Puri, P., Eicken, C., et al. (2008) Nonalcoholic Steatohepatitis Is Associated with Altered Hepatic MicroRNA Expression. Hepatology, 48, 1810-1820. https://doi.org/10.1002/hep.22569
|
[25]
|
Xie, X., Liao, H., Dang, H., et al. (2009) Down-Regulation of Hepatic HNF4alpha Gene Expression during Hyperinsulinemia via SREBPs. Molecular Endocrinology, 23, 434-443. https://doi.org/10.1210/me.2007-0531
|
[26]
|
Malhotra, P., Aloman, C., Ankireddy, A., et al. (2017) Overactivation of Intestinal Sterol Response Element-Binding Protein 2 Promotes Diet-Induced Nonalcoholic Steatohepatitis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 313, G376-G385. https://doi.org/10.1152/ajpgi.00174.2017
|
[27]
|
Svegliati-Baroni, G., Pierantonelli, I., Torquato, P., et al. (2019) Lipidomic Biomarkers and Mechanisms of lipotoXicity in Non-Alcoholic Fatty Liver Disease. Free Radical Biology and Medicine, 144, 293-309.
https://doi.org/10.1016/j.freeradbiomed.2019.05.029
|
[28]
|
Li, H., Yu, X.H., Ou, X., et al. (2021) Hepatic Cholesterol Transport and Its Role in Non-Alcoholic Fatty Liver Disease and Atherosclerosis. Progress in Lipid Research, 83, Article ID: 101109.
https://doi.org/10.1016/j.plipres.2021.101109
|
[29]
|
Lyu, J., Imachi, H., Fukunaga, K., et al. (2020) Role of ATP-Binding Cassette Transporter A1 in Suppressing Lipid Accumulation by Glucagon-Like Peptide-1 Agonist in Hepatocytes. Molecular Metabolism, 34, 16-26.
https://doi.org/10.1016/j.molmet.2019.12.015
|
[30]
|
Vega-Badillo, J., Gutiérrez-Vidal, R., Hernández-Pérez, H.A., et al. (2016) Hepatic miR-33a/miR-144 and Their Target Gene ABCA1 Are Associated with Steatohepatitis in Morbidly Obese Subjects. Liver International, 36, 1383-1391.
https://doi.org/10.1111/liv.13109
|
[31]
|
Yoon, H.Y., Lee, M.H., Song, Y., et al. (2021) ABCA1 69C>T Polymorphism and the Risk of Type 2 Diabetes Mellitus: A Systematic Review and Updated Meta-Analysis. Frontiers in Endocrinology, 12, Article ID: 639524.
https://doi.org/10.3389/fendo.2021.639524
|
[32]
|
Costet, P., Luo, Y., Wang, N., et al. (2000) Sterol-Dependent Transactivation of the ABC1 Promoter by the Liver X Receptor/Retinoid X Receptor. Journal of Biological Chemistry, 275, 28240-28245.
https://doi.org/10.1074/jbc.M003337200
|
[33]
|
Ioannou, G.N., Morrow, O.B., Connole, M.L. and Lee, S.P. (2009) Association between Dietary Nutrient Composition and the Incidence of Cirrhosis or Liver Cancer in the United States Population. Hepatology, 50, 175-184.
https://doi.org/10.1002/hep.22941
|
[34]
|
Van Rooyen, D.M., Larter, C.Z., Haigh, W.G., et al. (2011) Hepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic Steatohepatitis. Gastroenterology, 141, 1393-1403.E5.
https://doi.org/10.1053/j.gastro.2011.06.040
|
[35]
|
Yasutake, K., Nakamuta, M., Shima, Y., et al. (2009) Nutritional Investigation of Non-Obese Patients with Non-Alcoholic Fatty Liver Disease: The Significance of Dietary Cholesterol. Scandinavian Journal of Gastroenterology, 44, 471-477. https://doi.org/10.1080/00365520802588133
|
[36]
|
Musso, G., Gambino, R., De Michieli, F., et al. (2003) Dietary Habits and Their Relations to Insulin Resistance and Postprandial Lipemia in Nonalcoholic Steatohepatitis. Hepatology, 37, 909-916.
https://doi.org/10.1053/jhep.2003.50132
|
[37]
|
Henkel, J., Alfine, E., Sain, J., et al. (2018) Soybean Oil-Derived Poly-Unsaturated Fatty Acids Enhance Liver Damage in NAFLD Induced by Dietary Cholesterol. Nutrients, 10, Article No. 1326. https://doi.org/10.3390/nu10091326
|
[38]
|
Comhair, T.M., et al. (2011) Dietary Cholesterol, Female Gender and n-3 Fatty Acid Deficiency Are More Important Factors in the Development of Non-Alcoholic Fatty Liver Disease than the Saturation Index of the Fat. Nutrition & Metabolism, 8, 4.
|
[39]
|
Marchesini, G., Petta, S. and Dalle, G.R. (2016) Diet, Weight Loss, and Liver Health in Nonalcoholic Fatty Liver Disease: Pathophysiology, Evidence, and Practice. Hepatology, 63, 2032-2043. https://doi.org/10.1002/hep.28392
|
[40]
|
Dongiovanni, P., Petta, S., Mannisto, V., et al. (2015) Statin Use and Non-Alcoholic Steatohepatitis in at Risk Individuals. Journal of Hepatology, 63, 705-712. https://doi.org/10.1016/j.jhep.2015.05.006
|
[41]
|
Muraoka, T., Aoki, K., Iwasaki, T., et al. (2011) Ezetimibe Decreases SREBP-1c Expression in Liver and Reverses Hepatic Insulin Resistance in Mice Fed a High-Fat Diet. Metabolism, 60, 617-628.
https://doi.org/10.1016/j.metabol.2010.06.008
|
[42]
|
Jun, B.G. and Cheon, G.J. (2019) The Utility of Ezetimibe Therapy in Nonalcoholic Fatty Liver Disease. The Korean Journal of Internal Medicine, 34, 284-285. https://doi.org/10.3904/kjim.2019.043
|
[43]
|
Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. (2015) Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial. The Lancet, 385, 956-965. https://doi.org/10.1016/S0140-6736(14)61933-4
|